Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 7,049 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Bronchiectasis
Interventions: Ciprofloxacin DPI (BAYQ3939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 39
States / cities: Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 34 more

Conditions: Healthy
Interventions: PF-05230907, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Social Anxiety, Social Anxiety Disorder
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Ulcerative Colitis
Interventions: Tilpisertib, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 23
States / cities: Dothan, Alabama • Lancaster, California • Murrieta, California + 20 more

Conditions: UC (Urothelial Cancer)
Interventions: Pembrolizumab, Epacadostat, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 22
States / cities: Tucson, Arizona • Orange, California • New Haven, Connecticut + 16 more

Conditions: Twin; Complicating Pregnancy, Postpartum Hemorrhage
Interventions: Methylergonovine, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: Up to 65 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions: Placebo, Doxazosin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cannabis Dependence, Marijuana Dependence
Interventions: Dronabinol, Placebo, Lofexidine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Roseville, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Obesity
Interventions: ARD-101, Placebo; Drug
Lead sponsor: Aardvark Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: Oteseconazole (VT-1161), Placebo; Drug
Lead sponsor: Mycovia Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more

Conditions: Healthy, Sleep
Interventions: PF-04457845 / matched placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Dengue
Interventions: Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Overweight, Obesity
Interventions: Semaglutide, Placebo (Semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Menopause, Irritable Mood
Interventions: Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 59 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 114
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 98 more

Conditions: Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Interventions: Pregnenolone, Placebo; Drug
Lead sponsor: Sherwood Brown, MD, PhD; Other
Eligibility: 21 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Dallas, Texas • Richardson, Texas

Conditions: Covid19
Interventions: Camostat, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Pleasanton, California • Stanford, California

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Canakinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Charlestown, Massachusetts • Stony Brook, New York

Conditions: Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more

Conditions: Atopic Dermatitis
Interventions: Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 35
States / cities: Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 1356, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 24
States / cities: Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more

Conditions: Sleep Disturbances Associated With Menopause
Interventions: Elinzanetant, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: Little Port Walter, Alaska • Scottsdale, Arizona • Encinitas, California + 17 more

Search by objective public record fields.

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Single Dose Study of PF-05230907 in Healthy Japanese Subjects

Cannabidiol to Reduce Anxiety Reactivity

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Prophylactic Methylergonovine for Twin Cesarean

The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

Combined Pharmacotherapy for Cannabis Dependency

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Study to Evaluate ARD-101 in Adults With Obesity

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Estrogen Variability and Irritability During the Menopause Transition

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol

A Phase 1 QT Study in Healthy Male Subjects

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause